Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
6(85.7%)
Phase 3
1(14.3%)
7Total
Phase 2(6)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06696820Phase 2Completed

Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke

Role: lead

NCT07594314Phase 2Recruiting

Minocycline After Successful Endovascular Thrombectomy Recanalization in Acute Anterior Circulation Large Vessel Occlusion (ATTRACTION-MINOA)

Role: lead

NCT07594301Phase 2Recruiting

Minocycline After Successful Endovascular Thrombectomy Recanalization in Posterior Circulation Arterial Occlusion (ATTRACTION-MINOP)

Role: lead

NCT07162064Phase 3Completed

Heparin for RAO Post-Transradial Angiography in AIS

Role: lead

NCT06265051Phase 2Completed

Tirofiban After Successful MT Recanalization in AIS

Role: lead

NCT07302854Phase 2Recruiting

Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion

Role: lead

NCT07240467Phase 2Not Yet Recruiting

Bovis Calculus Stativus Treat Acute Cerebral Ischemic Stroke With Impaired Consciousness

Role: lead

All 7 trials loaded